A research study for treatment of mild to moderate ulcerative colitis with ayurvedic drugs and comparison with Allopathic treatment

A non randomized pilot study for treatment of mild to moderate cases of ulcerative colitis with Ayurvedic drugs in comparison to standard Allopathic treatment protocol - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/05/067117

Enrollment

Registered

2024-05-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K518- Other ulcerative colitis

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age 18 years of age - 60 years of age 2. Irrespective of caste, religion , sex mild to moderate cases of ulcerative colitis (mayo’s score 3-10 and true and witts criteria) 3.previous diagnosed case of ulcerative colitis.

Exclusion criteria

Exclusion criteria: 1.patient above 60 years and below 18 years of age 2.Toxic mega colon/ Fulminant type of disease 3.Severe type of Ulcerative colitis (Mayo score 11-12) 4.Known active infection (TB, HIV, C. Dificile, CMV) 5.Gastro intestinal perforation 6.Infective colitis, ischemic colitis, solitary ulcer syndrome, irradiation colitis 7.Lactose intolerance. 8.Pregnant females 9.known malignancy

Design outcomes

Primary

Measure	Time frame
Disease specific subjective parameters on true love’s and witts score . Colonoscopic tissue biopsy for diagnosis of ulcerative colitis Colonoscopic Mayo’s scoring for disease activityTimepoint: oral medications for period of 12 weeks followed by follow up every 4 weeks once for period of 12 weeks	—

Secondary

Measure	Time frame
Assessment of disease activity by follow up colonoscopy by mayos scoring assessment Assessment of symptoms of disease via subjective parameters using true loves & witts criteriaTimepoint: After 12 weeks drug will be further continued for 24 weeks with 4 weeks follow up to avoid relapse	—

Countries

India

Contacts

Public ContactDr Ajinkya machindra gadge

Institute of medical sciences Banaras Hindu University

rajinkya1630@gmail.com08080773959

Outcome results